Biogen resurrects Alzheimer's drug; shares jump 37%

Biogen Inc on Tuesday made a surprising reversal on its Alzheimer's treatment with plans now to seek U.S. regulatory approval, after data from more patients in two discontinued studies showed that the drug improved cognition at high doses.